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Introduction: 123I-N-isopropyl-p-iodoamphetamine (123I-IMP) is metabolized and 
converted to 123I-p-iodoamphetamine (123I-PIA) by CYP2C19 in humans.  Since 
variations in 123I-PIA levels reflect variations in CYP2C19 activity, CYP2C19 activity 
can be estimated by quantitative analysis of 123I-PIA levels. Thus, 123I-IMP 
administration can provide diagnostic information not only regarding cerebral blood 
flow (rCBF) but also regarding metabolic function.  The aim of the present study was 
to detect variations in CYP activity in mice using metabolite analysis.  Methods: 
Metabolism of 125I-IMP in pooled homogenates of mouse liver (MLH) was analyzed by 
high-performance liquid chromatography (HPLC) in the presence or absence of 
NADPH.  The amount of 125I-PIA generated was calculated as the normalized peak 
area of the chromatogram.  Inhibition of 125I-IMP metabolism was evaluated using the 
inhibitor SKF-525A.  A biodistribution study of 125I-IMP was performed to determine 
the organ distribution of 125I-IMP/125I-IMP metabolites and the effect of SKF-525A.  
Variations in CYP activity in vivo were detected by administration of 123I-IMP and/or 
SKF-525A to mice. The liver and the kidney were then excised, homogenized and 
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analyzed using HPLC.  Results: 125I-IMP was metabolized by MLH in the presence of 
NADPH, and the production of 125I-PIA was inhibited by SKF-525A.  SKF-525A did 
not greatly affect the biodistribution of 125I-IMP/125I-IMP metabolites in vivo.  Both 
123I-IMP and 123I-PIA were detected in organs of control mice.  However, 123I-PIA was 
not detected in the livers or kidneys of mice treated with SKF-525A.  Conclusions: 
CYP activity in vivo was inhibited by SKF-525A treatment. Variations in CYP activity 
could be detected in the blood, liver and kidney as changes in the peak area of 123I-PIA.  
Advances in Knowledge and Implications for patient Care:  123I-IMP metabolite 
analysis has the potential to provide beneficial information for prediction of the effect of 
medicines, in addition to its contribution to more accurate rCBF diagnosis that reflects 









The ideal radiopharmaceutical is generally not metabolized and does not 
undergo a structural change in vivo.  Radiopharmaceuticals can be used for both tissue 
accumulation studies and/or for tissue metabolic studies. For the former study, the ideal 
radiopharmaceutical is generally not metabolized and does not undergo a structural 
change in vivo.  For the latter study, the ideal radiopharmaceutical is only metabolized 
after its accumulation in the target tissue.  An important feature of nuclear medicine 
images is that these images reflect biological functions.  Radiopharmaceuticals that are 
administered to the body provide information regarding the biological functions that are 
involved in their accumulation, which vary according to the chemical structure of the 
radiopharmaceutical.  If the structure of the radiopharmaceutical changes before it 
goes into the tissues, then the behavior of this modified radiopharmaceutical will differ 
from that of the administered parental radiopharmaceutical.  Thus, nuclear medicine 
images obtained with such a radiopharmaceutical would not accurately reflect 
biological function.  However, some radiopharmaceuticals are known to be 
metabolized in vivo and such radiopharmaceuticals can provide important biological 
5 
ArticleIMP 
data [1].  In particular, 123I-N-isopropyl-p-iodoamphetamine (123I-IMP) is metabolized 
in stages and converted to 123I-p-iodoamphetamine (123I-PIA)[2]. 
Currently, 123I-IMP is widely used in clinical practice to examine regional 
cerebral blood flow (rCBF)[3, 4]. The input function of 123I-IMP is calculated based on 
octanol-water partition coefficients because the lipophilic nature of the 123I-IMP 
metabolites gradually decrease as 123I-IMP is metabolized.  However, 123I-IMP can 
potentially provide not only rCBF data but also data regarding another important 
diagnostic parameter; CYP activity.  Our research group has identified CYP2C19 as 
the enzyme that metabolizes N-isopropyl-p-iodoamphetamine (cold-IMP) and has 
shown using high-performance liquid chromatography (HPLC) that CYP2C19 converts 
cold-IMP to p-iodoamphetamine (cold-PIA) in pooled microsomes from human liver 
(HLM) [5].   
CYP2C19 is one of the cytochrome P450 enzymes that are involved in the 
metabolism of medicines [6].  However, four phenotypes of the CYP2C19 gene are 
expressed; extensive metabolizer (EM), intermediate metabolizer (IM), poor 
metabolizer (PM), and ultra-rapid metabolizer (UM)[7].  In general, a PM has little 
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ability to metabolize medicines, and therefore is susceptible to side effects of such 
medicines.  Thus, if PM is the only, or the major CYP2C19 gene expressed, the 
subject is susceptible to side effects of normal doses of administered commonly-used 
medications.  
It is therefore important to establish a method for measurement of the 
medicine-metabolizing capacity of individuals.  Our research group focused on 
analysis of the metabolites of 123I-IMP as a means of quantifying CYP2C19 activity in 
individuals.   Since changes in 123I-PIA production may reflect variations in CYP2C19 
activity, it should be possible to determine CYP2C19 activity in individuals by 
quantitative analysis of their 123I-PIA levels following 123I-IMP administration.   
In the present study, we aimed to detect variations in CYP activity in a living 
organism by performing metabolic experiments in mice. These data can be used as a 




Materials and Methods 
Materials 
Reagent-grade chemicals (e.g. potassium dihydrogenphosphate, dipotassium 
hydorogenphosphate, disodium edetate dihydrate, 60% perchloric acid, p-chlorobenzoic 
acid, and acetonitrile) were purchased from Nacalai Tesque (Kyoto, Japan).  Β-NADP+ 
and glucose-6-phosphate dehydrogenase were obtained from Oriental Yeast (Osaka, 
Japan).  SKF-525A was obtained from Enzo Life Science (Zandhoven, Belgium).  
125I-IMP and 123I-IMP were provided free by Nihon Medi-Physics (Chiba, Japan). 
 
Preparation of pooled homogenates of mouse liver (MLH) 
Animal studies were approved by the Animal Care Committee at Kanazawa 
University and were conducted in accordance with international standards for animal 
welfare and institutional guidelines. 
Six male mice (ddY, 6 weeks old, Japan SLC, Tokyo, Japan) were euthanized 
with anesthesia using diethyl ether.  The liver was then removed and weighed.  After 
addition of Krebs-Ringer phosphate buffer (KRPB, pH 7.4) to the livers, the mixture 
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was homogenized using an ultrasonic homogenizer.  The protein content was 
quantified using the bicinchoninic acid method [8]. 
 
Metabolism of 125I-IMP by MLH 
NADPH-dependent metabolism of 125I-IMP (370 kBq) by the pooled MLH 
samples was examined in an incubation mixture consisting of 100 mM sodium 
potassium phosphate buffer (pH 7.4), 50 μM EDTA disodium salt, and 250, 500, 1000 
or 2000 μg protein/10 μL pooled MLH in a final volume of 250 μL, in the presence or 
absence of an NADPH-generating system (0.5 mM NADP+, 5 mM MgCl2, 5 mM 
glucose-6-phosphate, and 1U/mL glucose-6-phosphate dehydrogenase).  A mixture 
without MLH or NADPH was used as the control.  The mixture was incubated at 
37 °C for 20, 40 or 60 min.  The reaction was stopped by adding 50 μL perchloric acid 
following which p-chlorobenzoic acid (20 μM, 30 μL) was added as an internal standard 
for ultraviolet (UV) detection.  Subsequently, the mixture was centrifuged for 5 min at 
18000 g, and 100 μL supernatant was analyzed using HPLC equipped with UV and 
gamma (γ) -ray detectors. 
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SKF-525A inhibition of 125I-IMP metabolism by MLH 
SKF-525A was used as a selective CYP inhibitor [9, 10].  Inhibition of 125I-IMP 
(370 kBq) metabolism by pooled MLH was examined in an incubation mixture 
consisting of 100 mM sodium potassium phosphate buffer (pH 7.4), SKF-525A (final 
concentration of 1, 5, 10 or 15 μM), 50 μM EDTA disodium salt and 1000 μg 
protein/10 μL MLH in a final volume of 250 μL, in the presence or absence of the 
NADPH-generating system. 
The mixture was incubated at 37 °C for 20 min.  The reaction was stopped by 
adding perchloric acid, following which 20 μM p-chlorobenzoic acid was added as the 
internal standard. Subsequently, these samples were centrifuged for 5 min at 18000 g, 
and 100 μL supernatant was analyzed using HPLC. 
 
Biodistribution studies of 125I-IMP in mice 
These studies were performed to evaluate the effects of SKF-525A on the 
biodistribution of administered 125I-IMP.  Male mice (ddY, 6 weeks old) were 
pretreated with SKF-525A in saline solution (1.25 μM, 100 μL) or with saline alone 
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(100 μL), and, after 3 min, 125I-IMP (18.5 kBq, 100 μL) was administered via the tail 
vein.  Mice were sacrificed at 2, 5, 10, 15 and 20 min after injection of 125I-IMP by 
cervical dislocation under deep ether anesthesia, and blood and organs of interest were 
removed.  Organs were weighed and their radioactivity was then determined using a 
scintillation counter.  The ratio of radioactivity accumulated per injected dose (ID) per 
organ weight was determined after decay correction and is expressed as a percentage 
(%ID/g). 
 
Metabolism of 123I-IMP and its inhibition by SKF-525A in mice 
Mice were pretreated with or without SKF-525A (1.25 μM, 100 μL) in saline 
solution, and, 3 min later, 123I-IMP (7.4 MBq, 100 μL) was administered via the tail 
vein.  Fifteen minutes after 123I-IMP injection, mice were sacrificed by cervical 
dislocation under deep ether anesthesia.  Blood was collected and deproteinized by 
adding 50 μL perchloric acid.  Subsequently, the mixture was centrifuged for 5 min at 
18000 g, and 100 μL supernatant was analyzed using HPLC.  The liver and kidney 
were excised and weighed.  After addition of KRPB to the liver and kidney, the 
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mixture was homogenized using an ultrasonic homogenizer.  The homogenates were 
deproteinized by adding perchloric acid, centrifuged for 5 min at 18000 g, and 100 μL 
supernatant was analyzed using HPLC. 
 
HPLC analysis of 125I- or 123I-IMP 
125I- or 123I-IMP and p-chlorobenzoic acid were analyzed using an HPLC system 
consisting of a pump (model L-7100, Hitachi, Tokyo, Japan), an UV detector (model 
SPD-10A), SHIMADZU, Tokyo, Japan) and a γ-ray detector (model RLC-701, 
Hitachi-Aloka Medical, Japan) equipped with a 5C18 AR-II column (4.6 × 250 mm; 5 
μm, Nacalai Tesque).  The mobile phase consisted of 60% (v/v) 20 mM potassium 
phosphate buffer (pH 3.0) and 40% acetonitrile.  Signal intensity was expressed as 
voltage (V, or mV).  The amount of 125I- or 123I-PIA was evaluated as the normalized 
peak area (%).  The normalized peak area of 125I- or 123I-PIA was defined as follows: 
Ratio of the peak area of 125I- or 123I-PIA to the total area of significant peaks. 
 
Selection of radioactive isotope (RI) 
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125I-IMP was used instead of 123I-IMP for in vitro experiments and the 
biodistribution study because of its longer half-life.  However, to detect radioactivity 
in the in vivo CYP activity assay using the HPLC system, it was necessary to have high 
levels of radioactivity in the homogenates of the excised organs.  Unfortunately, the 
concentration of 125I-IMP in the homogenates was too low for detection by this assay.  
Since the volume of 125I-IMP solution that would contain the required radioactivity was 




All results represent the average of least three experiments and are expressed as 
the mean ± SD.  Data were analyzed using Student’s t-test, and P < 0.05 was 




125I-IMP metabolism to 125I-PIA in MLH was analyzed using HPLC.  In in 
vitro experiments, the peaks of parental 125I-IMP and the metabolite 125I-PIA were 
detected in an incubation mixture containing an NADPH-generating system as shown in 
Figure 1A.  In contrast, only parental 125I-IMP was detected in a reaction mixture in 
the absence of the NADPH-generating system (Fig. 1B).  The normalized peak area of 
125I-PIA increased depending on the incubation time and the MLH concentration (Fig. 
2).  At each incubation time, the normalized peak area of 125I-PIA was maximal at 
1000 μg protein/sample, and was lower at 2000 μg protein/sample due to NADPH 
depletion. 
In the metabolic inhibition experiment in vitro, 125I-PIA production was reduced 
in a concentration-dependent manner following addition of the selective CYP inhibitor 
SKF-525A (Fig. 3).  The normalized peak area of 125I-PIA was reduced by 
approximately 50% in the presence of 10 μM SKF-525A. 
Tables 1A and 1B show the in vivo biodistribution of 125I (125I-IMP plus 
125I-PIA) in each mouse organ as a percentage of the injection dose /g tissue (%ID/g) or 
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/mL blood (%ID/mL) in the absence (1A) or presence (1B) of SKF-525A.  In both the 
control and the SKF-525A group, 125I (125I-IMP plus 125I-PIA) showed higher 
accumulation in the kidney compared to other organs except for the lung, and the level 
of radioactivity in the blood was very low.  In addition, no radioactivity was detected 
in the urine.  Figure 4 shows the in vivo data for blood, liver and kidney from Table 1 
in graph form and compares the effect of SKF-525A on accumulated radioactivity.  
There was no significant difference in the radioactive blood levels (A), or in the 
accumulated radioactivity levels in the liver (B) between the groups with or without 
SKF-525A.  However, in the kidney (C), the accumulated level of 125I-IMP plus 
125I-PIA at 5 min was higher in the SKF-525A group than in the control group (p < 
0.05).  These results indicate slightly faster distribution of 125I-IMP plus 125I-PIA to the 
kidney following co-administration of SKF-525A. 
In HPLC analysis of the blood of mice administered 123I-IMP, peaks of parental 
123I-IMP and the metabolite 123I-PIA were detected in both the control and the 
SKF-525A groups.  However, the normalized peak area of 123I-PIA was markedly and 
significantly reduced compared with the control group due to the SKF-525A loading.  
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Moreover, whereas peaks of both 123I-IMP and 123I-PIA were detected in organ 
homogenates prepared from control mice, only a peak of parental 123I-IMP was detected 




Considerable individual differences exist in the pharmacokinetics of humans.  
In most cases, the differences result from individual differences in the activity of 
drug-metabolizing enzymes as typified by CYP.  Genetic polymorphisms are cited as 
the main factors responsible for individual differences in the activity of 
drug-metabolizing enzymes [11, 12].  Individuals with very low or very high 
metabolic capacities exist due to genetic polymorphisms in CYP, and are described as 
PM and EM respectively [13, 14].  Currently, such individual differences at the genetic 
level are distinguished by genetic analysis.  However, genetic analysis cannot 
determine individual metabolic capacity at a particular point of time, which involves a 
variety of factors such as concomitant ingestion of different medicines, alcohol intake 
and deterioration in liver function due to aging.  On the other hand, our method based 
on metabolite analysis can measure an individual’s metabolic capability that reflects all 
of the factors described above.  As previously indicated, to date 123I-IMP has only been 
used to examine rCBF.  However, based on our data, 123I-IMP will be able to provide 
diagnostic information regarding metabolic function.  On a relevant note, it will also 
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be possible to accurately calculate input function by measuring the amount of an 
123I-IMP metabolite because the ratio of lipophilic metabolites that contaminate the 
octanol fraction will change according to the CYP activity of the individual patient.  
Thus, the present study provides an important basis for accurate assessment of input 
function and for establishment of an index that can be used to determine the dose of 
medicine to be prescribed for individuals.  In brief, competition with 123I-IMP can be 
used for dose determination of medicines that are non-radioactive and are substrates of 
CYP2C19, such as imipramine, clomipramine, omeprazole and cimetidine.  These 
non-radioactive medicines inhibit metabolism of 123I-IMP in a similar manner to 
SKF-525A. 
 In our previous study with HLM, cold-IMP was metabolized by CYP2C19 to 
cold-PIA [5].  However, IMP-metabolizing enzymes in mice have not been identified, 
and important species differences are present between humans and mice.  In addition, 
the number of molecules of 125I- or 123I-IMP that are accumulated in HLM or in organs 
after in vivo administration is very low. For these reasons, it was necessary to detect 
125I- or 123I-IMP, as well as cold-IMP, using an analytical method such as HPLC. 
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CYPs are drug-metabolizing enzymes that act when NADPH is present as an 
energy source [15].  In in vitro experiments, 125I-IMP and 125I-PIA were detected with 
high sensitivity using HPLC, and we confirmed that 125I-IMP was metabolized and 
converted to125I-PIA only in the presence of NADPH.  In addition, the normalized area 
of the 125I-PIA peak increased in a manner that was dependent on the protein 
concentration of MLH and on the incubation time (Fig. 2).  We therefore concluded 
that the metabolism of 125I-IMP was due to an enzymatic reaction.  Based on these 
results, the protein concentration and incubation time were set at 1000 µg/sample and 
20 min respectively, because a sufficient normalized peak area was obtained under these 
conditions that permitted evaluation of changes in the amount of 125I-PIA. 
The aim of the in vitro experiments of metabolic inhibition was to confirm that 
IMP is metabolized by mouse CYP.  Since it is unknown which CYP family 
metabolizes 125I-IMP in mice, we used SKF-525A as a CYP inhibitor, because 
SKF-525A inhibits the function of CYP regardless of the family or subfamily 
classification of CYP.  The normalized area of the 125I-PIA peak was reduced in an 
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SKF-525A concentration-dependent manner (Fig. 3).  Based on these results, we 
inferred that 125I-IMP was metabolized by CYP in mice as well as in humans. 
In the biodistribution study, 125I-PIA cannot be distinguished from 125I-IMP, 
because they both contain the same radionuclide; 125I.  Therefore this study evaluated 
the overall biodistribution of 125I-IMP including 125I-IMP metabolites.  This 
biodistribution study indicated a significant difference in the accumulation of 
125I-IMP/125I-IMP metabolites in the kidney at 5 min between the control and the 
SKF-525A group.  However, no significant difference was found in the accumulation 
of 125I-IMP at other times or in other tissues between the two groups.  Thus, we 
observed few significant alterations in the pharmacokinetics of 125I-IMP due to 
preloading of SKF-525A.  In both the control and SKF-525A groups, radioactivity in 
organs had almost reached equilibrium 15 min after administration of 125I-IMP, 
indicating that tissue migration of 125I-IMP had reached a steady state at this time point.  
As shown in Table 2, following preloading of SKF-525A, the peak of 123I-PIA 
disappeared in the liver and kidney and the normalized peak area of 123I-PIA was 
significantly reduced in the blood.  We considered that these decreases in 123I-PIA 
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levels were caused by decreased CYP activity, and not by administration of SKF-525A 
because the radioactivity in other organs was not significantly altered (Table 1 and Fig. 
4).  
In general, careful consideration is necessary in discussion of the metabolism of 
medicines administered at different concentrations, because it is known that the velocity 
of metabolic enzymatic reactions depends on the concentration of the substrate, and, 
furthermore, that metabolic enzymes other than the CYP family are present.  However, 
when the focus is on one enzyme and its labeled substrate, it is possible to discuss the 
metabolism of the labeled substrate that is administered at tracer concentrations based 
on the premise that the species and function of the enzymes that metabolize this 
substrate do not change in the presence of a tracer concentration of the substrate.  An 
example of such a study is the microdose study reported by Tozuka et al [16].  The fact 
that there is no pharmacological change in in vivo conditions due to the presence of a 
tracer concentration of the substrate is an advantage in this kind of study.  In the 
present study, 123I-IMP administration does not exert a pharmacological effect because 
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123I-IMP is present in trace amounts.  However, the administered 123I-IMP would 
accurately reflect individual metabolic function.  
  Although the present experiments were performed using mice, we consider 
that the metabolic rate of 123I-IMP will similarly fluctuate depending on CYP activity in 
humans. 
In humans, a medicine that is a substrate for CYP2C19 would behave as a 
CYP2C19 inhibitor instead of SKF-525A.  Subsequent 123I-IMP metabolite analysis 
would then indicate variation in CYP2C19 activity due to ingestion of the medicine. 
In addition, the only radiopharmaceutical that can currently be used for CYP 
activity-measurement methods that are based on metabolic changes is 123I-IMP.  This is 
because radiopharmaceuticals used in this method must meet the following conditions: a 
metabolizing enzyme must have been identified, its metabolites must also be radioactive, 
and detection and separation from the parental substance must be easy.  This method of 
estimation of CYP activity using 123I-IMP metabolite analysis has the potential to 
contribute to more accurate functional diagnosis that reflects individual metabolic 
function, and to the establishment of an index for determination of the correct dose of 
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medicine to be administered in humans.  Therefore, this method will lead to the 




Our aim was to detect CYP activity in vivo by quantitative analysis of 123I-IMP 
metabolites.  In the present study, we have demonstrated the following:  First, 
123I-IMP and 123I-PIA in HMLC are detectable using HPLC.  Second, the normalized 
peak area of 123I-PIA decreased due to reduction of CYP activity caused by SKF-525A 
treatment.  Finally, variations in CYP activity in vivo were detected in the blood, liver, 
and kidney of mice as changes in the normalized area of the 123I-PIA HPLC peak.   
For clinical application, it is necessary that 123I-PIA can be detected in samples such 
as blood or urine that can be collected in a minimally invasive manner, instead of in 
liver or kidney.  In addition, it will be necessary to find a simpler method of analysis, 
such as thin-layer chromatography, instead of HPLC.  However, we confidently 
conclude that 123I-IMP metabolite analysis can be used to detect variations in CYP 
activity in vivo.  Consequently, metabolite analysis of 123I-IMP can potentially be used 
in a clinical setting as a method for rCBF analysis that reflects metabolic function and 
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Figure 1.  Chromatograms of in vitro metabolite analyses.  MLH (1000 μg 
protein/sample) was incubated in the presence (A) or absence (B) of NADPH for 60 
min and then analyzed by HPLC.  The peaks of parental 125I-IMP and of 125I-PIA are 
shown. 125I-PIA was only detected in the presence of NADPH.  
 
Figure 2.  Relationship between MLH protein concentration and the normalized peak 
area of 125I-PIA at each incubation time in vitro.  MLH at the indicated protein 
concentration was incubated with 125I-IMP for the indicated times in the presence of 
NADPH.  Samples were analyzed by HPLC and the normalized peak area of 125I-PIA 
was calculated.  Error bars represent the mean ± SD. 
 
Figure 3.  Effect of SKF-525A concentration on 125I-PIA generation in vitro.  MLH 
(1000 μg protein/sample) was incubated with 125I-IMP for 20 min in the presence of the 
indicated concentration of SKF-525A.  The normalized peak area of 125I-PIA was 
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determined using HPLC. Error bars represent the mean ± SD.  The normalized peak 
area of 125I-PIA decreased with increasing SKF-525A concentration. 
 
Figure 4.  Graphic analysis of the in vivo effect of SKF-525A on the accumulation of 
125I-IMP and its metabolites in specific organs.  Radioactive (125I ) levels in the blood 
(A), liver (B) and kidney (C) of mice pretreated with SKF-525A or saline for 3 min 
prior to injection of 125I-IMP, as indicated in Tables 1A and 1B, are shown in graph 
form.  ID; injected dose.  Error bars represent the mean ± SD.  *: P < 0.05 compared 





















TABLE 1-A Biodistribution of 125I-IMP and its metabolites in mice not 
pretreated with SKF-525A 
 
Time after 125I-IMP injection 
 
%ID/g was calculated with the following formula:  
100 × (cpm of organ / injected dose) / organ weight 
N.D.: Not detected 
 
TABLE 1-B  Biodistribution of 125I-IMP and its metabolites in mice pretreated 
with SKF-525A 
 
Time after 125I-IMP injection 
 
Organ 2 min  5 min  10 min  15 min  20 min 
Blood 0.87 ± 0.36  0.85 ± 0.03  0.91 ± 0.18  0.80 ± 0.29  0.81 ± 0.12 
Brain 5.95 ± 2.22  6.83 ± 0.21  7.52 ± 0.98  6.96 ± 2.27  7.31 ± 0.59 
Lung 17.88 ± 7.35  16.11 ± 2.11  18.91 ± 4.73  17.52 ± 5.53  16.32 ± 3.47 
Heart 5.32 ± 2.28  5.29 ± 0.67  5.44 ± 0.17  4.38 ± 1.54  4.42 ± 0.30 
Liver 3.35 ± 0.57  4.53 ± 0.10  5.85 ± 1.40  5.08 ± 1.25  4.76 ± 0.12 
Pancreas 6.89 ± 3.24  8.46 ± 1.37  9.87 ± 0.59  7.63 ± 3.71  9.87 ± 0.63 
Spleen 4.60 ± 1.84  5.83 ± 0.73  6.64 ± 0.75  6.80 ± 0.94  7.65 ± 0.52 
Stomach 3.68 ± 1.66  4.81 ± 1.32  7.67 ± 0.69  9.04 ± 3.63  9.24 ± 3.38 
Kidney 10.11 ± 2.46  11.90 ± 0.12  13.46 ± 1.52  12.01 ± 1.15  10.89 ± 1.10 
Intestine 2.09 ± 0.24  2.49 ± 0.15  3.24 ± 0.34  2.72 ± 0.71  2.52 ± 0.22 
Muscle 2.27 ± 0.67  2.83 ± 0.32  2.54 ± 0.25  1.99 ± 0.89  2.24 ± 0.19 
Urine N.D.  N.D.  N.D.  N.D.  N.D. 
Organ 2 min  5 min  10 min  15 min  20 min 
Blood 0.67 ± 0.07  0.64 ± 0.16  0.74 ± 0.11  0.74 ± 0.12  0.76 ± 0.04 
Brain 5.46 ± 0.48  5.36 ± 0.96  7.29 ± 1.96  6.42 ± 0.09  6.57 ± 0.26 
Lung 21.79 ± 5.60  16.82 ± 5.14  17.70 ± 4.65  13.82 ± 1.26  13.14 ± 1.79 
Heart 5.51 ± 0.85  4.06 ± 0.88  4.10 ± 0.98  3.93 ± 0.68  3.33 ± 0.02 
Liver 2.68 ± 0.29  3.44 ± 0.79  4.97 ± 0.43  4.67 ± 0.08  4.79 ± 0.19 
Pancreas 4.40 ± 1.61  6.85 ± 1.58  10.35 ± 2.22  11.16 ± 0.90  10.63 ± 0.24 
Spleen 2.49 ± 0.51  3.85 ± 0.63  8.15 ± 0.87  4.54 ± 1.62  6.66 ± 0.16 
Stomach 2.70 ± 0.48  3.42 ± 0.86  7.13 ± 2.10  7.05 ± 0.03  8.35 ± 1.88 
Kidney 7.92 ± 1.08  9.43 ± 1.25  11.87 ± 1.92  12.04 ± 0.54  10.33 ± 0.83 
Intestine 1.98 ± 0.15  2.13 ± 0.40  3.09 ± 0.38  2.75 ± 0.04  2.80 ± 0.19 
Muscle 2.77 ± 0.54  2.27 ± 0.19  2.19 ± 0.13  1.78 ± 0.15  1.90 ± 0.15 
Urine N.D.  N.D.  N.D.  N.D.  N.D. 
%ID/g was calculated with the following formula:  
100 × (cpm of organ / injected dose) / organ weight 





TABLE 2 Effect of SKF-525A on 123I-PIA levels in organs of 123I-IMP-treated 
mice. 
 
Organ Control Group   SKF-525A Group 
        Blood 25.78 ± 1.74  15.13 ± 1.10 
        Kidney 14.38 ± 7.31  N.D. 
        Liver 25.17 ± 7.61   N.D. 
 
The normalized area of the 123I-PIA peak in HPLC analysis is shown. N.D.: 
Not detectable 
 
 
